Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Purpose
Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC)...........................
http://ascopubs.org/doi/10.1200/JCO.2012.47.4940
Tivozanib war jetzt also nicht wirklich so viel besser als Sorafenib. Leider.